Researchers have studied various treatments for nightmares stemming from posttraumatic stress disorder, but the medications offered to patients have generally yielded poor results.
Sheryl Alexander is a recent graduate of the PA program at the University of North Dakota school of medicine & Health sciences, Grand Forks, North Dakota. the subject of her scholarly research project was pharmacologic management of post‐traumatic stress disorder. Susan Kuntz is an assistant professor of family and community medicine and PA program faculty at the University of North Dakota. the authors have indicated no relationships to disclose relating to the content of this article.
Symbol SEE THE ONLINE VERSION OF THIS ARTICLE TO LINK TO
ONGOING PHASE 3 CLINICAL TRIALS ON PRAZOSIN
National Institutes of Health; Efficacy of sleep interventions for PTSD www.clinicaltrials.gov/ct/show/NCT00393874?order=1
National Institutes of Health; Prazosin for treating noncombat trauma post‐traumatic stress disorder www.clinicaltrials.gov/ct/show/NCT00183430?order=6
STUDY CURRENTLY RECRUITING (through 2012) National Institutes of Health; Prazosin and combat trauma PTSD (PACT) http://clinicaltrials.gov/ct2/show/NCT00532493?term=prazosin+and+ptsd&rank=1